This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to nucleobases 1479 through 1508 of a coding region of a nucleic acid molecule encoding human fibroblast growth factor receptor 2, wherein said compound is an antisense oligonucleotide, wherein said antisense oligonucleotide comprises at least one modified internucleoside linkage, and wherein said compound specifically hybridizes with said nucleic acid molecule encoding human fibroblast growth factor receptor 2 (SEQ ID NO: 3) and inhibits the expression of human fibroblast growth factor receptor 2.

Claims 2-4 (canceled).

Claim 5 (currently amended): The compound of ~~claim 4~~ claim 1 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (currently amended): The compound of ~~claim 2~~ claim 1 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety.

Claim 8 (currently amended): The compound of ~~claim 2~~ claim 1 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (currently amended): The compound of ~~claim 2~~ claim 1 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (canceled).

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (previously presented): A method of inhibiting the expression of fibroblast growth factor receptor 2 in cells or tissues comprising contacting said cells or tissues *in vitro* with the compound of claim 1 so that expression of fibroblast growth factor receptor 2 is inhibited.

Claims 16-20 (canceled).